



Synta to be Showcased in Congress as One of 13 Innovative Companies Seeking More Competitive American Business Environment

September 8, 2011

LEXINGTON, Mass., Sep 08, 2011 (BUSINESS WIRE) --

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that President and CEO [Safi Bahcall, Ph.D.](#) is meeting with House leaders to discuss policy initiatives that could support job creation and innovation in the U.S. economy. Synta is among 13 companies that are being highlighted as an example of innovative firms that are being hampered by government in their effort to create American jobs.

"Maintaining U.S. leadership in science and technology and addressing the serious healthcare issues facing this country require policies in place that encourage innovation," said Dr. Bahcall. "Reducing the barriers and increasing incentives to innovation can help companies like Synta and other biotechnology companies create new drugs, lower the total costs of healthcare by preventing expensive hospital stays and create new jobs in America."

Dr. Bahcall will attend the President's Address to a Joint Session of Congress this evening as a guest in the Speaker's Box.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities. For more information, please visit www.syntapharma.com.

SOURCE: Synta Pharmaceuticals Corp.

Synta Pharmaceuticals Corp.
Rob Kloppenburg, 781-541-7125